Excelimmune

About Excelimmune

Excelimmune, Inc. was a biopharmaceutical firm established in 2006 by Vincent Coljee, positioning itself to address critical needs in infectious disease treatment. The company operated from Woburn, Massachusetts, and focused on harnessing the human body's adaptive immune system to develop novel therapies. It was later reported that the company went out of business on October 1, 2017.

The core of Excelimmune's strategy was its proprietary Human Recombinant Polyclonal Antibody (HRPA) platform. This technology involved cloning naturally occurring human antibodies to create mixed populations of therapeutic antibodies. Unlike monoclonal antibodies that target a single epitope, these polyclonal antibodies could bind to multiple regions of an antigen, theoretically allowing the body to combat illnesses more effectively. The business model centered on the discovery and development of these antibody combination therapeutics, with plans to form strategic partnerships to expand the application of its HRPA technology into new therapeutic areas beyond infectious diseases.

Excelimmune's flagship product candidate was Staphguard, a human recombinant polyclonal antibody designed to combat methicillin-resistant Staphylococcus aureus (MRSA), a significant threat in nosocomial (hospital-acquired) infections. The company's technology was also aimed at broader applications, including other pathogenic bacteria, viruses, disease-causing proteins, and cancer. Throughout its operation, Excelimmune secured significant funding to advance its programs, including a $2M Series A round in 2007, a $10.5M Series B financing in May 2011, and an additional $12M in December 2011, bringing its total raised capital to over $14.5M. These funds were allocated to move Staphguard towards clinical trials, enhance the discovery platform, and establish proof-of-principle for its manufacturing systems.